79 related articles for article (PubMed ID: 33723299)
1. The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation.
Božič Mijovski M; Malmström RE; Vene N; Antovic JP; Mavri A
Sci Rep; 2021 Mar; 11(1):5920. PubMed ID: 33723299
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran antagonizes growth, cell-cycle progression, migration, and endothelial tube formation induced by thrombin in breast and glioblastoma cell lines.
Vianello F; Sambado L; Goss A; Fabris F; Prandoni P
Cancer Med; 2016 Oct; 5(10):2886-2898. PubMed ID: 27600331
[TBL] [Abstract][Full Text] [Related]
3. Supratherapeutic dabigatran: a cause of life-threatening haemorrhage.
Hennessy M; Reidy B; Ní Ainle F; Conneely J; McDermott C; Scanaill PÓ
Anaesth Rep; 2023; 11(1):e12208. PubMed ID: 36632350
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran pharmacokinetic-pharmacodynamic in sheep: Informing dose for anticoagulation during cardiopulmonary bypass.
Eaton MP; Nadtochiy SM; Stefanos T; Anderson BJ
Perfusion; 2024 Jan; ():2676591231226291. PubMed ID: 38171494
[TBL] [Abstract][Full Text] [Related]
5. Laboratory-guided repeat dosing of idarucizumab for dabigatran reversal.
Jones H; De Simone N; Webb C
Clin Toxicol (Phila); 2023 Aug; 61(8):622-623. PubMed ID: 37668187
[No Abstract] [Full Text] [Related]
6. Thrombin generation assay in platelet-poor plasma in children with iron deficiency anemia.
Özdöl U; Özdemir ZC; Töret E; Özen H; Bör Ö
Int J Lab Hematol; 2024 Apr; 46(2):345-353. PubMed ID: 38041255
[TBL] [Abstract][Full Text] [Related]
7. Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.
Hutcherson TC; Cieri-Hutcherson NE; Bhatt R
P T; 2017 Nov; 42(11):692-698. PubMed ID: 29089725
[TBL] [Abstract][Full Text] [Related]
8. Continuing Education Case Study Quiz.
Hosp Pharm; 2016 Mar; 51(3):263-265. PubMed ID: 38745582
[TBL] [Abstract][Full Text] [Related]
9. The effect of pH on thrombin generation-An unrecognized potential source of variation.
Kristensen SR; Nybo J; Pedersen S
Res Pract Thromb Haemost; 2020 Feb; 4(2):224-229. PubMed ID: 32110752
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of complement components C5 and C9 are associated with thrombin generation.
Vacik Díaz R; Munsch G; Iglesias MJ; Pallares Robles A; Ibrahim-Kosta M; Nourse J; Khan E; Castoldi E; Saut N; Boland A; Germain M; Deleuze JF; Odeberg J; Morange PE; Danckwardt S; Tregouët DA; Goumidi L
J Thromb Haemost; 2024 Jun; ():. PubMed ID: 38838952
[TBL] [Abstract][Full Text] [Related]
11. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
Cheung CL; Sing CW; Lau WCY; Li GHY; Lip GYH; Tan KCB; Cheung BMY; Chan EWY; Wong ICK
Cardiovasc Diabetol; 2021 Mar; 20(1):71. PubMed ID: 33766030
[TBL] [Abstract][Full Text] [Related]
12. Validity of different dose reduction criteria for apixaban.
Hawkins NM; Er L; Sandhu RK; Kaul P; McAlister FA; Levin A; Andrade JG
Am Heart J; 2021 Aug; 238():12-15. PubMed ID: 33762178
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk for intracranial hemorrhage related to new oral anticoagulants: A network meta-analysis.
Ma T; Liu C; Jiang T; Qin H; Wu R; Zhou P
Medicine (Baltimore); 2021 Mar; 100(12):e24522. PubMed ID: 33761634
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rivaroxaban and ticagrelor in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention.
Liu X; Wang L; Zhou M; Feng L
Contemp Clin Trials; 2021 May; 104():106365. PubMed ID: 33746024
[TBL] [Abstract][Full Text] [Related]
15. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.
Douxfils J; Adcock DM; Bates SM; Favaloro EJ; Gouin-Thibault I; Guillermo C; Kawai Y; Lindhoff-Last E; Kitchen S; Gosselin RC
Thromb Haemost; 2021 Aug; 121(8):1008-1020. PubMed ID: 33742436
[TBL] [Abstract][Full Text] [Related]
16. Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis.
Ferro JM; Bendszus M; Jansen O; Coutinho JM; Dentali F; Kobayashi A; Aguiar de Sousa D; Neto LL; Miede C; Caria J; Huisman H; Diener HC;
Int J Stroke; 2022 Feb; 17(2):189-197. PubMed ID: 33724104
[TBL] [Abstract][Full Text] [Related]
17. Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.
Jin J; Zhuo X; Xiao M; Jiang Z; Chen L; Devi Shamloll Y
Medicine (Baltimore); 2021 Mar; 100(12):e25185. PubMed ID: 33761699
[TBL] [Abstract][Full Text] [Related]
18. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment.
Hvas AM; Favaloro EJ; Hellfritzsch M
Expert Rev Hematol; 2021 Apr; 14(4):335-346. PubMed ID: 33736552
[No Abstract] [Full Text] [Related]
19. Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine.
Harenberg J; Martini A; Du S; Krämer S; Weiss C; Hetjens S
Clin Appl Thromb Hemost; 2021; 27():1076029621993550. PubMed ID: 33733904
[TBL] [Abstract][Full Text] [Related]
20. Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding.
Lee SR; Kwon S; Choi EK; Jung JH; Han KD; Oh S; Lip GYH
Cardiovasc Drugs Ther; 2022 Aug; 36(4):679-689. PubMed ID: 33730289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
